Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.07.113 on June 6 2005

Journal of Clinical Oncology, Vol 23, No 22 (August 1), 2005: pp. 4866-4875
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colucci, G.
Right arrow Articles by Maiello, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colucci, G.
Right arrow Articles by Maiello, E.
Related Articles
Right arrowRelated Editorial
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Giuseppe Colucci, Vittorio Gebbia, Giancarlo Paoletti, Francesco Giuliani, Michele Caruso, Nicola Gebbia, Giacomo Cartenì, Biagio Agostara, Giuseppe Pezzella, Luigi Manzione, Nicola Borsellino, Andrea Misino, Sante Romito, Ernesto Durini, Stefano Cordio, Marisa Di Seri, Massimo Lopez, Evaristo Maiello

From the Oncology Institute, Bari; University; La Maddalena Hospital; M. Ascoli Hospital, Palermo; Regina Elena Institute; La Sapienza University, Rome; Centro Oncologico; S. Luigi Hospital, Catania; Cardarelli Hospital, Naples; Ospedale Nord, Taranto; S. Carlo Hospital, Potenza; Cardarelli Hospital, Campobasso; G. Panico Hospital, Tricase, Italy

Address reprint requests to Giuseppe Colucci, MD, Medical and Experimental Oncology Unit, Oncology Institute, Via Amendola 209, 70126 Bari, Italy; e-mail: colucci{at}goim.it

PURPOSE: We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer.

PATIENTS AND METHODS: A total of 360 chemotherapy-naive patients were randomly assigned to receive, every 2 weeks, either arm A (FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2 [LV5FU2]) or arm B (FOLFOX4: oxaliplatin 85 mg/m2 on day 1 with LV5FU2 regimen).

RESULTS: One hundred sixty-four and 172 patients were assessable in arm A and B, respectively. Overall response rates (ORR) were 31% in arm A (95% CI, 24.6% to 38.3%) and 34% in arm B (95% CI, 27.2% to 41.5%; P = .60). In both arms A and B, median time to progression (TTP; 7 v 7 months, respectively), duration of response (9 v 10 months, respectively), and overall survival (OS; 14 v 15 months, respectively) were similar, without any statistically significant difference. Toxicity was mild in both groups: alopecia and gastrointestinal disturbances were the most common toxicities in arm A; thrombocytopenia and neurosensorial were the most common toxicities in arm B. Grade 3 to 4 toxicities were uncommon in both arms, and no statistical significant difference was observed.

CONCLUSION: There is no difference in ORR, TTP, and OS for patients treated with the FOLFIRI or FOLFOX4 regimen. Both therapies seemed effective as first-line treatment in these patients. The difference between these two combination therapies is mainly in the toxicity profile.

Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002; and at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorial

  • Whither Irinotecan?
    Charles D. Blanke
    JCO 2005 23: 4811-4814 [Full Text]


This article has been cited by other articles:


Home page
 Ann OncolHome page
W. Koizumi, N. Boku, K. Yamaguchi, Y. Miyata, A. Sawaki, T. Kato, Y. Toh, I. Hyodo, T. Nishina, T. Furuhata, et al.
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
Ann. Onc., October 14, 2009; (2009) mdp371v1.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
C. Eng and S. Kopetz
Commentary: Practice Patterns and Potential Impact on Quality Measures for a Practicing Physician
J. Oncol. Pract, September 1, 2009; 5(5): 233 - 235.
[Full Text] [PDF]

Home page
 Therapeutic Advances in Medical OncologyHome page
A. Grothey
Review: Medical treatment of advanced colorectal cancer in 2009
Therapeutic Advances in Medical Oncology, September 1, 2009; 1(2): 55 - 68.
[Abstract] [PDF]

Home page
 JCOHome page
G. A. van Hazel, N. Pavlakis, D. Goldstein, I. N. Olver, M. J. Tapner, D. Price, G. D. Bower, G. M. Briggs, M. A. Rossleigh, D. J. Taylor, et al.
Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy
J. Clin. Oncol., September 1, 2009; 27(25): 4089 - 4095.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. O'Connell
Oxaliplatin or Irinotecan As Adjuvant Therapy for Colon Cancer: The Results Are In
J. Clin. Oncol., July 1, 2009; 27(19): 3082 - 3084.
[Full Text] [PDF]

Home page
 JCOHome page
C. D. Blanke
Dual-Antibody Therapy in Advanced Colorectal Cancer: Gather Ye Rosebuds While Ye May
J. Clin. Oncol., February 10, 2009; 27(5): 655 - 658.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E. Aranda, M. Valladares, M. Martinez-Villacampa, M. Benavides, A. Gomez, B. Massutti, E. Marcuello, M. Constenla, J. C. Camara, A. Carrato, et al.
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Ann. Onc., February 1, 2009; 20(2): 251 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Sato, T. Suzuki, Y. Katayose, K. Miura, K. Shiiba, H. Tateno, Y. Miki, J. Akahira, Y. Kamogawa, S. Nagasaki, et al.
Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors
Cancer Res., February 1, 2009; 69(3): 914 - 922.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. H. O'Neil and R. M. Goldberg
In Reply
Oncologist, February 1, 2009; 14(2): 194 - 196.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. Grothey
Optimized Treatment of Metastatic Colorectal Cancer
ASCO Educational Book, January 1, 2009; 2009(1): 209 - 211.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. McKibbin and J. M. Koeller
In Reply
Oncologist, January 1, 2009; 14(1): 106 - 107.
[Full Text] [PDF]

Home page
 J Oncol PractHome page
K. M. Field, S. Kosmider, M. Jefford, R. Jennens, M. Green, and P. Gibbs
Chemotherapy Treatments for Metastatic Colorectal Cancer: Is Evidence-Based Medicine in Practice?
J. Oncol. Pract, November 1, 2008; 4(6): 271 - 276.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. McKibbin, C. R. Frei, R. E. Greene, P. Kwan, J. Simon, and J. M. Koeller
Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting
Oncologist, August 1, 2008; 13(8): 876 - 885.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. F. Sobrero, J. Maurel, L. Fehrenbacher, W. Scheithauer, Y. A. Abubakr, M. P. Lutz, M. E. Vega-Villegas, C. Eng, E. U. Steinhauer, J. Prausova, et al.
EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., May 10, 2008; 26(14): 2311 - 2319.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, and T. Gruenberger
Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer
J. Clin. Oncol., April 10, 2008; 26(11): 1830 - 1835.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Prewett, D. S. Deevi, R. Bassi, F. Fan, L. M. Ellis, D. J. Hicklin, and J. R. Tonra
Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab
Clin. Cancer Res., December 15, 2007; 13(24): 7432 - 7440.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Tabernero, E. Van Cutsem, E. Diaz-Rubio, A. Cervantes, Y. Humblet, T. Andre, J.-L. Van Laethem, P. Soulie, E. Casado, C. Verslype, et al.
Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5225 - 5232.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Grothey
Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?
Clin. Cancer Res., November 15, 2007; 13(22): 6909s - 6912s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. S. Fuchs, J. Marshall, E. Mitchell, R. Wierzbicki, V. Ganju, M. Jeffery, J. Schulz, D. Richards, R. Soufi-Mahjoubi, B. Wang, et al.
Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study
J. Clin. Oncol., October 20, 2007; 25(30): 4779 - 4786.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu
Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy
J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. J. Meropol
A Renewed Call for Equipoise
J. Clin. Oncol., August 10, 2007; 25(23): 3392 - 3394.
[Full Text] [PDF]

Home page
 JCOHome page
A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crino, G. Benedetti, W. Evangelista, L. Fanchini, et al.
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
J. Clin. Oncol., May 1, 2007; 25(13): 1670 - 1676.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg, M. L. Rothenberg, E. Van Cutsem, A. B. Benson III, C. D. Blanke, R. B. Diasio, A. Grothey, H.-J. Lenz, N. J. Meropol, R. K. Ramanathan, et al.
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Oncologist, January 1, 2007; 12(1): 38 - 50.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg
Therapy for Metastatic Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 981 - 987.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. H. O'Neil and H. L. McLeod
Thymidine Phosphorylase and Capecitabine: A Predictive Marker for Therapy Selection?
J. Clin. Oncol., September 1, 2006; 24(25): 4051 - 4053.
[Full Text] [PDF]

Home page
 JCOHome page
S. Benoist, A. Brouquet, C. Penna, C. Julie, M. El Hajjam, S. Chagnon, E. Mitry, P. Rougier, and B. Nordlinger
Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?
J. Clin. Oncol., August 20, 2006; 24(24): 3939 - 3945.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. D. Yan, D. Black, R. Savady, and P. H. Sugarbaker
Systematic Review on the Efficacy of Cytoreductive Surgery Combined With Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis From Colorectal Carcinoma
J. Clin. Oncol., August 20, 2006; 24(24): 4011 - 4019.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Goto, Y. Yamada, H. Yasui, K. Kato, T. Hamaguchi, K. Muro, Y. Shimada, and K. Shirao
Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer
Ann. Onc., June 1, 2006; 17(6): 968 - 973.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Innocenti, E. E. Vokes, and M. J. Ratain
Irinogenetics: What Is the Right Star?
J. Clin. Oncol., May 20, 2006; 24(15): 2221 - 2224.
[Full Text] [PDF]

Home page
 JCOHome page
J. A. Meyerhardt, A. X. Zhu, P. C. Enzinger, D. P. Ryan, J. W. Clark, M. H. Kulke, C. C. Earle, M. Vincitore, A. Michelini, S. Sheehan, et al.
Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastastic Colorectal Cancer
J. Clin. Oncol., April 20, 2006; 24(12): 1892 - 1897.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. D. Blanke
Whither Irinotecan?
J. Clin. Oncol., August 1, 2005; 23(22): 4811 - 4814.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online